peptide dosing chart
10 mg in 2 mL = 5 mg/mL, so 250 mcg is 0.05 mL = 5 units on a U-100 syringe.
Every row is what a specific FDA label or registered human trial used, with the source linked. Where no human dosing study exists, the chart says so instead of repeating forum numbers.
mL
syringe · picked to fit the draw
price, vial size and certificate correction
USD
mL
Most 2–15 mg vials hold 3 mL.
mg
From the lot certificate; it replaces the label amount.
%
draw 5 units
0.05 mL on a 0.3 mL U-100 syringe
- concentration
- 5 mg/mL
- per unit
- 50 mcg per unit
- full draws per vial
- 40
- cost per draw
- —
the working
- 10 mg ÷ 2 mL = 5 mg/mL
- 250 mcg ÷ 5 mg/mL = 0.05 mL
- 0.05 mL × 100 = 5 units on a 0.3 mL U-100 syringe
- 10 mg ÷ 250 mcg = 40 → 40 full draws
If this is a prescription, the dose and volume on your pharmacy label take priority. Ask your pharmacist about any mismatch.
FDA labels · human trials · sources linked
doses used in labels and trials
| compound | evidence | what the source used | calculator |
|---|---|---|---|
| 5-Amino-1MQ | animal studies only | No human trials are registered or published; the evidence is cell and mouse studies of this NNMT inhibitor. The catalogue lists both vials and oral capsules. | calculate |
| ACE-031 | human trials | Phase 2 (NCT01099761): 1.0 mg/kg SC every 2 weeks: 1 mg/kg every 2 weeks, subcutaneousPhase 2 (NCT01099761): 0.5 mg/kg SC every 4 weeks: 0.5 mg/kg every 4 weeks, subcutaneous | calculate |
| Adamax | no published dosing data | No peer-reviewed human or animal studies were found for this compound. | calculate |
| Adipotide | animal studies only | Not approved; the main evidence is a study in obese rhesus monkeys (Sci Transl Med 2011). The only human trial, a phase 1 in obese men with metastatic prostate cancer (NCT01262664), was terminated after 4 participants with no posted or published results. | calculate |
| AHK-Cu | not dosed by injection | Cosmetic copper peptide with no human dosing study; the published evidence is ex vivo human hair follicles and cultured dermal papilla cells (PMID 17703734). | calculate |
| AICAR | human trials | Phase 3 RED-CABG (JAMA 2012): 0.1 mg/kg/min IV for 7 hours around CABG surgery: 42 mg/kg single continuous IV infusion at 0.1 mg/kg per minute for about 7 hours, intravenousPhase I/II (Cancer Chemother Pharmacol 2013): single 4-hour IV infusions in relapsed CLL: 210 mg/kg single 4-hour infusion (part II: 2 or 5 doses at 210 mg/kg), intravenous | calculate |
| AOD-9604 | human trials | Phase 2b METAOD006: 1 mg oral daily for 24 weeks (largest trial): 1 mg once daily, oralPhase 2b METAOD005: 1-30 mg oral daily for 12 weeks: 30 mg once daily, oral | calculate |
| ARA-290 | human trials | Phase 2b (IOVS 2017, NCT02039687): 1, 4 or 8 mg SC daily: 4 mg once daily, subcutaneousPhase 2 (Mol Med 2015): 4 mg SC daily in type 2 diabetes: 4 mg once daily, subcutaneous | calculate |
| BPC-157 | small human studies | Phase 1 registration (PCO-02, NCT02637284): oral 1 mg tablets: 3 mg three times daily, oralHuman pilot (Altern Ther Health Med 2025): 10 mg then 20 mg IV infusion: 10 mg → 20 mg single infusion on day 1, then single infusion on day 2, intravenous | calculate |
| BPC-157 / TB-500 | no published dosing data | No study has tested this blend; catalogue vials hold BPC-157/TB-500 at 5/5, 10/10 or 20/20 mg (plus spray and 0.5/0.5 mg capsule forms), and component human evidence is limited to small BPC-157 pilot reports, with none for TB-500. | calculate |
| BPC-157 / TB-500 / MGF | no published dosing data | No study has tested this blend; the catalogue vial holds BPC-157 10 mg / TB-500 7.5 mg / MGF 1 mg, and of the components only BPC-157 has human data (small pilot reports), with none for TB-500 or MGF. | calculate |
| Bronchogen | animal studies only | No human dosing studies; published work is rat COPD models and cell or tissue culture. | calculate |
| Cagrilintide | human trials | Phase 3 REDEFINE 1 (NEJM 2025): cagrilintide 2.4 mg weekly monotherapy arm: 2.4 mg once weekly, subcutaneousPhase 3 REDEFINE 1 (NEJM 2025): cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (CagriSema): 2.4 mg once weekly, subcutaneous | calculate |
| Cardiogen | no published dosing data | Only tissue-culture (rat heart explant) studies were found; no human or in-vivo dosing data. | calculate |
| Cartalax | no published dosing data | No human or animal dosing studies were found. | calculate |
| Cerebrolysin | approved outside the US | Russian label: acute ischemic stroke 10-50 mL IV once daily: 10 mL once daily, intravenousCARS Phase 2 (Stroke 2016): 30 mL IV once daily for 21 days: 30 mL once daily, intravenous | calculate |
| Chonluten | no published dosing data | Only cell-culture studies (e.g., THP-1 monocytes) were found; no human or animal dosing data. | calculate |
| CJC-1295 (DAC) | human trials | Phase 1 multiple-dose study (JCEM 2006): 20-60 mcg/kg: 60 mcg/kg every 2 weeks (2 injections, days 0 and 14), subcutaneousPhase 1 single ascending dose (JCEM 2006): 30-250 mcg/kg: 250 mcg/kg single dose, subcutaneous | calculate |
| CJC-1295 (No DAC) | no published dosing data | The non-DAC form (modified GRF 1-29) has no FDA or ex-US label, and no registered human trial or published human dosing study of it was found; published human GHRH-analog dosing belongs to sermorelin or to albumin-binding CJC-1295 with DAC, not to this peptide. | calculate |
| CJC-1295 (No DAC) / GHRP-6 | no published dosing data | No label and no registered or published human study of this combination was found; GHRP-6 has short human physiology studies on its own, while CJC-1295 (No DAC) has none. | calculate |
| Cortagen | animal studies only | No human dosing studies; evidence is rat injection studies and tissue culture. | calculate |
| Dermorphin | small human studies | Human pilot (J Clin Endocrinol Metab 1983): 5.5 mcg/kg per minute IV for 30 min: 5.5 mcg/kg per minute as a single 30-minute intravenous infusion, intravenousHuman pilot (Brain Res 1986): 0.16 mg/kg IV infusion: 0.16 mg/kg single intravenous infusion, intravenous | calculate |
| Dihexa | animal studies only | No human studies; evidence is rodent work, chiefly McCoy et al. 2013 (J Pharmacol Exp Ther), which has carried an expression of concern since 2021. | calculate |
| DSIP | approved outside the US | Russian label (Deltaran 0.3 mg intranasal): 1-3 ampoules a day: 0.3 mg 1-3 ampoules per day, intranasalDouble-blind study (Neuropsychobiology 1992): 25 nmol/kg IV: 25 other once daily, in the afternoon, intravenous | calculate |
| Epithalon | small human studies | No approved use; a Russian clinical report (retinitis pigmentosa, 2002) gives no dose in the indexed abstract, and the most-cited dosing data come from mice. | calculate |
| Follistatin 344 | no published dosing data | No approved product and no human trial of follistatin-344 protein; registered human follistatin trials are AAV gene transfer of the FS344 gene (e.g. NCT01519349), which gives no peptide dose. The protein literature is forensic detection of black-market material (PMID 31758732) and a case series of central serous chorioretinopathy in 11 bodybuilders after high-dose injection (PMID 32671599). | calculate |
| FOXO4-DRI | animal studies only | No human studies; the evidence is mouse work, chiefly Baar et al. (Cell 2017). | calculate |
| GHK-Cu | human trials | Not approved as a drug; human evidence is topical only: a randomized venous-ulcer trial of a 0.4% tripeptide-copper cream (no benefit over placebo, PMID 1495150) and a randomized trial of daily GHK-Cu gel (Iamin) in diabetic neuropathic ulcers (PMID 17147644); neither abstract gives a reproducible dose, and no injectable human study exists. | calculate |
| GHK-Cu / KPV / BPC-157 | no published dosing data | No study has tested this blend; the catalogue vial holds GHK-Cu 50 mg / KPV 10 mg / BPC-157 10 mg, and component human evidence is topical-only for GHK-Cu, small pilot reports for BPC-157 and none for KPV. | calculate |
| GHRP-2 | approved outside the US | Japan label (GHRP Kaken 100): 100 mcg IV, adults: 100 mcg single dose, intravenousJapan label: 2 mcg/kg IV, ages 4 to under 18: 2 mcg/kg single dose, intravenous | calculate |
| GHRP-6 | human trials | Dose-ranging in normal men (JCEM 1990): 0.1-1.0 mcg/kg IV: 1 mcg/kg single dose, intravenousSex/age physiology study: 1 mcg/kg IV: 1 mcg/kg single dose, intravenous | calculate |
| GLOW | no published dosing data | No study has tested this blend; catalogue vials hold GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg (also listed as a 70 mg total and 150/30/30 mg), and component human evidence is topical-only for GHK-Cu, small pilot reports for BPC-157 and none for TB-500. | calculate |
| GLOW (GHK-Cu / TB4 / BPC-157) | no published dosing data | No study has tested this blend; the catalogue vial holds GHK-Cu 50 mg / thymosin beta-4 10 mg / BPC-157 10 mg, and component human evidence is topical-only for GHK-Cu, phase 1-2 trials for thymosin beta-4 and small pilot reports for BPC-157. | calculate |
| Glutathione | approved outside the US | Italian SmPC (Tationil 600 mg): 1-2 vials a day IM or slow IV: 600 mg once or twice daily (1-2 vials of 600 mg), intramuscularPhase 2b (J Parkinsons Dis 2017): intranasal 200 mg three times daily: 200 mg three times daily, intranasal | calculate |
| Gonadorelin | approved outside the US | UK SmPC: 100 mcg single diagnostic dose: 100 mcg single dose, intravenousCanadian monograph (Lutrepulse): 5 mcg per pulse every 90 minutes: 5 mcg every 90 minutes by pulsatile pump, intravenous | calculate |
| HCG | FDA-approved | Pregnyl label: ovulation induction, 5,000-10,000 units once: 10000 IU single dose, intramuscularPregnyl label: male hypogonadotropic hypogonadism: 4000 IU 3 times weekly → 2000 IU 3 times weekly 3 times weekly, intramuscular | calculate |
| Hexarelin | human trials | 16-week study: 1.5 mcg/kg SC twice daily: 1.5 mcg/kg twice daily, subcutaneous24-h secretion study: 1.5 mcg/kg SC two or three times daily: 1.5 mcg/kg two or three times daily, subcutaneous | calculate |
| hGH Fragment 176-191 | animal studies only | No human dosing trial is registered or published under this name; the evidence is rodent and in-vitro work on C-terminal hGH 177-191 peptides (Biochem Mol Biol Int 1993-1994). The related analogue AOD9604 (Tyr-hGH 177-191) has separate oral human data; see AOD-9604. | calculate |
| Humanin | animal studies only | No human administration studies found; human data measure endogenous circulating humanin, and dosing work is in rodents and cells. | calculate |
| IGF-1 DES | animal studies only | No FDA or ex-US label and no registered or published human trial of des(1-3)IGF-I; the cited literature is rodent work and laboratory reviews, e.g. 0.96 mg/kg/day by osmotic pump in rats after gut resection (PMID 1996625). | calculate |
| IGF-1 LR3 | animal studies only | No FDA or ex-US label and no registered human trial; the cited literature on Long-R3-IGF-I is animal and cell-culture work. | calculate |
| Ipamorelin | human trials | Phase 2 (NCT00672074): 0.03 mg/kg IV twice daily: 0.03 mg/kg twice daily, intravenousPhase 1 PK/PD: 4.21-140.45 nmol/kg IV infusion: 140.45 other single 15-minute infusion, intravenous | calculate |
| Ipamorelin / CJC-1295 | no published dosing data | No label and no registered or published human study of this combination was found; the catalogue blend pairs ipamorelin with CJC-1295 (No DAC), and the non-DAC component has no published human dosing study either. | calculate |
| Kisspeptin-10 | human trials | Dose-response in men (JCEM 2011): 0.01-3 mcg/kg IV bolus: 1 mcg/kg single bolus, intravenousInfusion in men: 1.5 or 4 mcg/kg/h for up to 22.5 h: 4 mcg/kg per hour by continuous infusion, intravenous | calculate |
| KLOW | no published dosing data | No study has tested this blend; catalogue vials hold GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg (also listed as an 80 mg total and 150/30/30/30 mg), and component human evidence is topical-only for GHK-Cu, small pilot reports for BPC-157 and none for TB-500 or KPV. | calculate |
| KLOW (GHK-Cu / TB4 / BPC-157 / KPV) | no published dosing data | No study has tested this blend; the catalogue vial holds GHK-Cu 50 mg / thymosin beta-4 10 mg / BPC-157 10 mg / KPV 10 mg, and component human evidence is topical-only for GHK-Cu, phase 1-2 trials for thymosin beta-4, small pilot reports for BPC-157 and none for KPV. | calculate |
| KPV | animal studies only | No human dosing study; evidence is in vitro (including human keratinocytes and dermatomed human skin permeation) and murine colitis models (for example KPV added to drinking water), none of which gives a per-kg dose usable as a human reference. | calculate |
| Liraglutide | FDA-approved | Saxenda label (FDA): weekly titration to 3 mg daily: 0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3 mg once daily, subcutaneousVictoza label (FDA): 0.6 mg start, then 1.2 mg, maximum 1.8 mg daily: 0.6 mg → 1.2 mg → 1.8 mg once daily, subcutaneous | calculate |
| Livagen | no published dosing data | Only cell- and tissue-culture studies (including cultured lymphocytes from elderly donors) were found; no human or animal dosing data. | calculate |
| LL-37 | human trials | Phase 2b HEAL LL-37 (Wound Repair Regen 2021): 0.5 or 1.6 mg/mL topical: 0.5 other twice weekly, topicalFirst-in-human RCT (Wound Repair Regen 2014): 0.5, 1.6 or 3.2 mg/mL topical: 0.5 other twice weekly, topical | calculate |
| Mazdutide | approved outside the US | Phase 3 GLORY-1 (NEJM 2025): 6 mg weekly arm: 2 mg → 4 mg → 6 mg once weekly, subcutaneousPhase 3 GLORY-2 (JAMA 2026): 9 mg weekly for 60 weeks: 9 mg once weekly, subcutaneous | calculate |
| Melanotan-1 | FDA-approved | Scenesse label (FDA): 16 mg implant SC every 2 months: 16 mg one implant every 2 months, subcutaneousPhase 3 (NEJM 2015): 16 mg implant every 60 days: 16 mg one implant every 60 days, subcutaneous | calculate |
| Melanotan-2 | small human studies | Pilot phase I (Life Sci 1996): 0.01 mg/kg SC, escalated to 0.025-0.03 mg/kg: 0.01 mg/kg every other day, alternating with saline, Monday to Friday, subcutaneousCrossover pilot (Urology 2000): 0.025 mg/kg SC, two injections: 0.025 mg/kg administered twice (and vehicle twice) in a crossover, subcutaneous | calculate |
| MGF | no published dosing data | Mechano-growth factor has no FDA or ex-US label, and no registered human trial or published human dosing study was found. | calculate |
| MOTS-c | animal studies only | No published human dosing; a Phase 2a trial (NCT07505745) is recruiting but its record states no dose and has no results. The founding mouse study used 0.5 mg/kg/day IP. | calculate |
| N-Acetyl Epitalon Amidate | no published dosing data | No peer-reviewed human or animal studies of this modified epitalon were found. | calculate |
| N-Acetyl Semax Amidate | no published dosing data | No peer-reviewed human dosing studies of the N-acetyl amidated form were found; the registered Russian product is unmodified Semax. | calculate |
| NAD+ | small human studies | Pilot study (Front Aging Neurosci 2019): 750 mg IV over 6 h: 750 mg single infusion, intravenous | calculate |
| Ovagen | no published dosing data | No human or animal dosing studies were found. | calculate |
| Oxytocin | FDA-approved | Pitocin label: labour induction, 0.5-1 mU/min titrated: 0.5-1 mU/min (initial) → +1-2 mU/min every 30-60 min → 9-10 mU/min (rarely exceeded) continuous infusion in mU/min, increased every 30-60 minutes, intravenousPitocin label: postpartum bleeding, 10 units IM: 10 IU single dose after delivery of the placenta, intramuscular | calculate |
| P21 | animal studies only | No human studies; P021 has been studied only in mouse and rat models. | calculate |
| Pancragen | animal studies only | No human dosing studies; evidence is rats with experimental diabetes, old rhesus monkeys and cell culture. | calculate |
| PE-22-28 | animal studies only | No human studies; evidence is mouse depression models (Djillani et al. 2017). | calculate |
| PEG MGF | no published dosing data | PEGylated mechano-growth factor has no FDA or ex-US label, and no registered human trial or published human dosing study was found. | calculate |
| Pinealon | small human studies | Only Russian occupational and gerontology reports (2012, 2015) describe pinealon use in people, and their indexed abstracts state no dose. | calculate |
| PNC-27 | animal studies only | No human dosing has been published; evidence is cell-culture work plus mouse models of acute myeloid leukemia. | calculate |
| Prostamax | no published dosing data | Only cell and tissue-culture studies (lymphocyte chromatin, prostate explants) were found; no human or animal dosing data. | calculate |
| PT-141 | FDA-approved | Vyleesi label (FDA): 1.75 mg SC as needed: 1.75 mg as needed, at least 45 minutes before anticipated sexual activity; no more than one dose within 24 hours, subcutaneousPhase 2b dose-finding (Womens Health 2016): 0.75, 1.25 or 1.75 mg SC: 1.75 mg self-administered as desired about 45 minutes before anticipated sexual activity; no more than one dose per day or 16 doses per 4 weeks, subcutaneous | calculate |
| Retatrutide | human trials | Phase 3 TRIUMPH-1 (NEJM 2026): 4, 9 or 12 mg weekly for 80 weeks: 12 mg once weekly, subcutaneousPhase 3 TRIUMPH-2 (Lancet 2026): obesity with type 2 diabetes, 4, 9 or 12 mg weekly: 12 mg once weekly, subcutaneous | calculate |
| Retatrutide / Cagrilintide | animal studies only | No registered or published human study has given retatrutide and cagrilintide together (ClinicalTrials.gov and PubMed checked 2026-11-04); the only combination data are in diet-induced obese male rats (Nat Metab 2026, PMID 42744908). | calculate |
| Selank | approved outside the US | Russian label (Selank 0.15%): 2 drops per nostril three times daily: 2 other three times daily, intranasal | calculate |
| Semaglutide | FDA-approved | Wegovy label (FDA): 16-week titration to 2.4 mg weekly: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg once weekly, subcutaneousOzempic label (FDA): type 2 diabetes titration, maximum 2 mg weekly: 0.25 mg → 0.5 mg → 1 mg → 2 mg once weekly, subcutaneous | calculate |
| Semax | approved outside the US | Russian label (Semax 1%): moderate ischemic stroke, 2,000-3,000 mcg per dose: 2000 mcg 3-4 times daily, 3-4 h apart, intranasalRussian label (Semax 0.1%): cognitive disorders, 200-2,000 mcg per dose: 200 mcg 4 times daily, intranasal | calculate |
| Semax / Selank | no published dosing data | No studies of the combined product were found; Semax and Selank are each registered separately in Russia as nasal drops. | calculate |
| Sermorelin | human trials | Geref International Study Group: 30 mcg/kg nightly: 30 mcg/kg once daily at bedtime, subcutaneousDiagnostic test (BioDrugs review 1999): 1 mcg/kg IV once: 1 mcg/kg single dose, intravenous | calculate |
| SLU-PP-332 | animal studies only | No human dosing studies; the evidence is mouse studies (ACS Chem Biol 2023; J Pharmacol Exp Ther 2024) and in-vitro work on human myoblasts (Front Physiol 2025). The catalogue lists both vials and oral capsules. | calculate |
| SNAP-8 | not dosed by injection | Cosmetic peptide (acetyl octapeptide-3); PubMed lists no human dosing study of the peptide on its own, only multi-ingredient formulations. The 5 mg and 10 mg vials are lyophilized and the 200 mg item is a topical-formulation powder. | calculate |
| SS-31 | FDA-approved | Forzinity label: 40 mg SC once daily: 40 mg once daily, subcutaneousMMPOWER-3 Phase 3 (Neurology 2023): 40 mg SC daily: 40 mg once daily, subcutaneous | calculate |
| Survodutide | human trials | Phase 3 SYNCHRONIZE-1 (NEJM 2026): up to 6.0 mg weekly for 76 weeks: 6 mg once weekly, subcutaneousPhase 2 obesity dose-finding (Lancet Diabetes Endocrinol 2024): 4.8 mg weekly arm: 0.3 mg → 0.6 mg → 0.9 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.3 mg → 4.2 mg → 4.8 mg once weekly, subcutaneous | calculate |
| TB-500 | animal studies only | No human study of TB-500 has been completed or published; the literature describes it as a synthetic version of an active region of thymosin beta-4 (equine doping-control work, PMID 23084823), so full-length thymosin beta-4 trial doses do not transfer, and the only ClinicalTrials.gov record (NCT07487363) describes itself as a fictional example. | calculate |
| TB-500 Fragment (17-23) | animal studies only | No human dosing study of the Ac-LKKTETQ (thymosin beta-4 17-23) fragment exists; published work is analytical (equine doping control) and preclinical, and full-length thymosin beta-4 trial data do not apply to the fragment. | calculate |
| Tesamorelin | FDA-approved | EGRIFTA WR label: 1.28 mg daily: 1.28 mg once daily, subcutaneousEGRIFTA SV label: 1.4 mg daily: 1.4 mg once daily, subcutaneous | calculate |
| Tesamorelin / Ipamorelin | no published dosing data | No label and no registered or published human study of this combination was found; tesamorelin and ipamorelin have each been studied alone (see their own entries). | calculate |
| Testagen | no published dosing data | No biological dosing studies were found; indexed items are cell-penetration and materials-chemistry papers (an unrelated testosterone product shares the name on ClinicalTrials.gov). | calculate |
| Thymalin | approved outside the US | Russian package insert (Samson-Med): 5-20 mg IM daily: 5 mg once daily, intramuscular | calculate |
| Thymogen | approved outside the US | Russian label (Thymogen 0.01% injection): 100 mcg IM once daily: 100 mcg once daily, intramuscular | calculate |
| Thymosin Alpha-1 | approved outside the US | Zadaxin prescribing information (SciClone): chronic hepatitis B, 1.6 mg SC twice weekly: 1.6 mg twice weekly, subcutaneousItalian SmPC (AIC 028364026): influenza-vaccine adjuvant, one 1.6 mg vial twice weekly: 1.6 mg twice weekly, subcutaneous | calculate |
| Thymosin Beta-4 | human trials | Phase 2 (NCT00832091): topical gel 0.01%, 0.03% or 0.1% w/w on venous stasis ulcers: 0.1 other once daily, topicalPhase 2 (NCT01387347): 0.1% w/w eye drops (RGN-259) in dry eye: 0.1 other twice daily, each eye, topical | calculate |
| Tirzepatide | FDA-approved | Zepbound label (FDA): 2.5 mg start, 2.5 mg steps to 5, 10 or 15 mg weekly: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg once weekly, subcutaneousMounjaro label (FDA): type 2 diabetes, 2.5 mg steps to a 15 mg maximum: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg once weekly, subcutaneous | calculate |
| Triptorelin | FDA-approved | TRELSTAR label: 3.75 / 11.25 / 22.5 mg depot: 22.5 mg every 24 weeks (3.75 mg every 4 weeks; 11.25 mg every 12 weeks), intramuscularTRIPTODUR label: 22.5 mg every 24 weeks: 22.5 mg every 24 weeks, intramuscular | calculate |
| Vesugen | small human studies | Russian reports in truck drivers (2012) and in 32 adults with polymorbidity (2015) describe vesugen use, but their indexed abstracts state no dose; other work is in cells and animals. | calculate |
| Vilon | small human studies | Small Russian clinical studies (type 1 diabetes 2006-2007; elderly colorectal cancer 2005) report vilon use, but their indexed abstracts state no dose. | calculate |
| VIP | approved outside the US | Invicorp SmPC (ANSM, France): 25 mcg aviptadil + 2 mg phentolamine intracavernosal: 25 mcg no more than once daily and no more than three times weekly, otherPhase 3 TESICO (Lancet Respir Med 2023): IV 12-h infusions escalating 600/1200/1800 pmol/kg: 600 pmol/kg → 1200 pmol/kg → 1800 pmol/kg one 12-hour infusion daily, intravenous | calculate |
Each row records what a specific FDA label or registered human trial used. It is not a recommendation; doses for a person are set by a prescriber.
what the numbers mean · where they come from
terms and sources
- Label amount or measured amount. The calculator starts from the amount printed on the vial. A lot certificate’s measured content (net peptide content, in mg) can replace it for the vial that was tested. HPLC purity is a share of peak area, not a mass, so a purity-only correction is shown as an estimate. See HPLC, certificate of analysis and how to read a peptide COA.
- Concentration. Amount in the vial ÷ water added. Terms: reconstitution, bacteriostatic water, lyophilized.
- Syringe units. A volume: 0.01 mL per unit on a U-100 syringe, 0.025 mL on U-40. Units say nothing about the compound until the concentration is known.
- Cost per draw. Vial price × amount per draw ÷ vial amount, from the price per mg of a current offer. Price history: peptide price tracker.
Arithmetic only, on the numbers entered. Amounts from labels or trials are cited references, not recommendations; PeptideTech does not give personal use instructions and does not test products.
short answers
calculator questions
Where do these doses come from?
Each row cites an FDA label (DailyMed), an ex-US label or a registered or published human trial. Research peptides without human dosing studies are listed as such rather than given a number.
Is this a dosing recommendation?
No. It records what specific labels and studies used, for reference. Doses for a person are set by a prescriber; if you have a prescription, its label takes priority.
more calculators